Literature DB >> 23780507

Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.

Amit S Chitnis1, Stacy M Holzbauer, Ruth M Belflower, Lisa G Winston, Wendy M Bamberg, Carol Lyons, Monica M Farley, Ghinwa K Dumyati, Lucy E Wilson, Zintars G Beldavs, John R Dunn, L Hannah Gould, Duncan R MacCannell, Dale N Gerding, L Clifford McDonald, Fernanda C Lessa.   

Abstract

IMPORTANCE: Clostridium difficile infection (CDI) has been increasingly reported among healthy individuals in the community. Recent data suggest that community-associated CDI represents one-third of all C difficile cases. The epidemiology and potential sources of C difficile in the community are not fully understood.
OBJECTIVES: To determine epidemiological and clinical characteristics of community-associated CDI and to explore potential sources of C difficile acquisition in the community. DESIGN AND
SETTING: Active population-based and laboratory-based CDI surveillance in 8 US states. PARTICIPANTS: Medical records were reviewed and interviews performed to assess outpatient, household, and food exposures among patients with community-associated CDI (ie, toxin or molecular assay positive for C difficile and no overnight stay in a health care facility within 12 weeks). Molecular characterization of C difficile isolates was performed. Outpatient health care exposure in the prior 12 weeks among patients with community-associated CDI was a priori categorized into the following 3 levels: no exposure, low-level exposure (ie, outpatient visit with physician or dentist), or high-level exposure (ie, surgery, dialysis, emergency or urgent care visit, inpatient care with no overnight stay, or health care personnel with direct patient care). MAIN OUTCOMES AND MEASURES: Prevalence of outpatient health care exposure among patients with community-associated CDI and identification of potential sources of C difficile by level of outpatient health care exposure.
RESULTS: Of 984 patients with community-associated CDI, 353 (35.9%) did not receive antibiotics, 177 (18.0%) had no outpatient health care exposure, and 400 (40.7%) had low-level outpatient health care exposure. Thirty-one percent of patients without antibiotic exposure received proton pump inhibitors. Patients having CDI with no or low-level outpatient health care exposure were more likely to be exposed to infants younger than 1 year (P = .04) and to household members with active CDI (P = .05) compared with those having high-level outpatient health care exposure. No association between food exposure or animal exposure and level of outpatient health care exposure was observed. North American pulsed-field gel electrophoresis (NAP) 1 was the most common (21.7%) strain isolated; NAP7 and NAP8 were uncommon (6.7%). CONCLUSIONS AND RELEVANCE: Most patients with community-associated CDI had recent outpatient health care exposure, and up to 36% would not be prevented by reduction of antibiotic use only. Our data support evaluation of additional strategies, including further examination of C difficile transmission in outpatient and household settings and reduction of proton pump inhibitor use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23780507     DOI: 10.1001/jamainternmed.2013.7056

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  145 in total

1.  A hospital-based study of the clinical characteristics of Clostridium difficile infection in children.

Authors:  Jonathan D Crews; Hoonmo L Koo; Zhi-Dong Jiang; Jeffrey R Starke; Herbert L DuPont
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

Review 2.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

3.  Proton Pump Inhibitor-Associated C. difficile Infection in a Peritoneal Dialysis Patient.

Authors:  Susan L Ziolkowski; Michelle H Malabanan; Scott E Liebman
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

4.  A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015.

Authors: 
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

Review 5.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

Review 6.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

7.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

8.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

Review 9.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

10.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

Authors:  Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.